Overview

Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure

Status:
Completed

Trial end date:
2019-07-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Dapagliflozin